A Precision-Medicine Framework for Redox-Fragile Populations Core thesis: Historic pathogen pressure, including plague, may have shaped population-level immune and redox differences, while modern clinical development remains overly dependent on European-ancestry biology. ReBalU proposes a genotype- and biomarker-guided way to identify redox-fragile individuals and restore
The most expensive stock on Earth might also be the best acquisition currency ever created. Here's why — and where SpaceX should spend it first. The Setup Five days after the largest IPO in history, SpaceX trades at ~$2.7 trillion. At ~94x 2025 revenue, SPCX carries one of
Equity Research Report IPO reference: $135/share (June 11, 2026) — the largest IPO in history ★ RECOMMENDATION: STRONG BUY ★ SpaceX (SPCX) — Reference $135 | Dramatically Undervalued vs. Perfect-Execution Value Our conviction view. We rate SPCX a major BUY. We believe SpaceX will execute. Our perfect-execution scenarios imply a value many
How a Monopoly on Reusable Space Infrastructure Routes the Global Economy Through the United States and Makes SPCX a Generational Long-Term Buy Executive Summary On June 12, 2026, SpaceX went public on the NASDAQ under ticker SPCX at $135 per share, raising a base of ~$75 billion — expandable to
How a quiet iOS update confirmed what I've been writing for a year and what it means for companies, services, and chips. Executive Summary Apple has quietly partnered with SpaceX and T-Mobile to bring Starlink satellite messaging directly to the iPhone through a recent software update, breaking
Thesis Update — The Track Holds Through May, But Stronger. The Supply Build Is Now Three-Sided. The Update in One Line Through May 2026, the 1927 overlay is holding month by month, but running hotter, because AI is a more powerful leadership engine than radio ever was, and because the
The Lowest-Cost Chronic-Disease Aggregation Platform Meets a Structurally Engineered Short Squeeze ★ MAJOR BUY RECOMMENDATION ★ Status: Pre-Catalyst (Nasdaq compliance deadline: June 30, 2026) Executive Summary We rate Vivos Therapeutics (NASDAQ: VVOS) a MAJOR BUY on the strength of two independent and coequal pillars, each of which would justify
In 2024, 12th-grade NAEP math and reading scores hit their lowest levels ever recorded. The usual suspects lined up immediately — pandemic learning loss, screen time, chronic absenteeism, underfunding. All plausible. But the decline started well before COVID, and none of those explanations account for a pattern hiding in plain
The Companies Powering the Buildout and Why the Smartest Money on Wall Street Is Crowding In A nine-company infrastructure portfolio including AmpliTech Group (NASDAQ: AMPG) as a featured essential play and positioned for the largest capital-deployment cycle in modern history. Executive Summary The artificial-intelligence buildout has become
★ MAJOR BUY RECOMMENDATION ★ AmpliTech Group (NASDAQ: AMPG) The Forgotten Winner of the Satellite-to-Phone Trade PART I — Recommendation: MAJOR BUY (AMPG) This is a major buy recommendation on a totally overlooked stock. Wall Street is staring at the wrong end of the satellite-to-cell revolution — fixated on Starlink&
How ReBalU's endogenous butyrate and DHA systematically influence 18 validated longevity genes, and how the test/treat/retest platform compensates for the genetic insufficiencies that determine how fast you age. This is Part Two of a two-part series on the ReBalU protocol and longevity biology. Part One
Horizon: 24 Months (through May 2028) | Rating: Strategic Buy / Acquisition Candidate Current Price: $5.23 | 24-Month Blended Target: $28.40 | Upside: +443% Strategic Takeout Range: $13.00 – $32.00 | Standalone Discounted Range: $41 – $70 1. Executive Summary AmpliTech Group is the only US supplier of a commercial-grade 64T64R